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Abstract
Background: Blood product transfusion occurs in a significant percentage of intensive care unit (ICU) patients.
Pulmonary complications, such as acute respiratory distress syndrome (ARDS), occurring in the setting of transfusion,
are associated with increased morbidity and mortality. Contrary to the ICU setting, there is little evidence describing
the epidemiology of transfusion in the emergency department (ED) or its potential impact on outcome. The objectives
of this study were to: (1) characterize transfusion practices in the ED with respect to patient characteristics and
pre-transfusion laboratory values; and (2) investigate the effect of ED blood product transfusion on the incidence
of pulmonary complications after admission. We hypothesized that blood product transfusion would increase the
event rate for pulmonary complications, and have a negative impact on other clinically significant outcomes.
Methods: This was a retrospective case-control study with one-one matching of 204 transfused ED patients to 204
non-transfused controls. The primary outcome was a composite pulmonary outcome that included: acute
respiratory failure, new need for ICU admission, and ARDS. Multivariable logistic regression was used to evaluate the
primary outcome as a function of transfusion.
Results: One-hundred twenty four (60.8%) patients were transfused packed red blood cells (PRBC) in the ED. The
mean pre-transfusion hemoglobin level was 8.5 g/dl. There were 73 patients with a hemoglobin value ≥10 g/dl; 19
(26.0%) received a PRBC transfusion. A total of 54 (26.5%) patients were transfused platelets. The main indications
were thrombocytopenia (27.8%) and neurologic injury (24.1%). Ten patients had a platelet level <10,000 (guideline
recommended threshold for transfusion to prevent spontaneous hemorrhage). The mean platelet count for
neurologic injury patients was 197,000 prior to transfusion. The primary outcome occurred in 26 control patients
(12.7%), as compared with 28 cases (13.7%). In multivariable logistic regression analysis, ED transfusion was not
associated with an increased odds of primary outcome [adjusted OR 0.91 (0.48–1.72), P = 0.77]. The mortality rate
was 10.8% in the cases and 8.8% in the controls, P = 0.51.
Conclusions: A significant percentage of ED blood product transfusions are discordant with guideline recommendations.
However, there was no association with ED transfusion and worse clinical outcome.
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Background
In a general intensive care unit (ICU) population, 20–50%
of patients are transfused blood products during their ICU
stay [1]. The previous two decades have seen intense
investigation into transfusion practices, and their impact
on outcome in the ICU [2–4]. This has led to a well-
defined epidemiology of transfusion practices in the ICU,
and evidence-based guideline recommendations in the
critical care setting [5]. The emergency department (ED)
is the entry point for the majority of patients in the ICU.
Excluding massive transfusion protocols in the setting of
major trauma, there is little evidence describing transfu-
sion in the ED setting or its potential impact on outcome.
Blood product transfusion is associated with well-
documented risks. From a pulmonary perspective, this
includes an association with acute respiratory distress
syndrome (ARDS), transfusion-related acute lung injury
(TRALI), and transfusion-associated circulatory overload
(TACO) [6–10]. Development of these pulmonary compli-
cations is associated with an increase in morbidity and
mortality. As there is increased interest in prevention of
pulmonary complications (such as ARDS) after ICU ad-
mission, describing the potential impact that ED-based
transfusion has, could be an important step in improving
outcome [11].
The objectives of this study were to: (1) characterize
the transfusion practices in the ED with respect to
patient characteristics and pre-transfusion laboratory
values; and (2) investigate the effect of ED blood product
transfusion on the incidence of pulmonary complications
after admission. We hypothesized that blood product
transfusion would increase the event rate for pulmonary
complications, and have a negative impact on other
clinically significant clinical outcomes.
Methods
Study design
This was a retrospective case-control study and is
reported in accordance with The Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement: Guidelines for Reporting Observa-
tional Studies [12]. The funding organizations played no
role in the conduct and reporting of the study. Ethics
approval was obtained from the Human Research
Protection Office at the corresponding author’s institu-
tion with waiver of informed consent.
Study setting and population
This study was conducted at a university-affiliated,
urban teaching hospital (1250 beds), with an annual ED
census of >95,000 patients. Over a 4-year period (June
2009 to May 2013), adult patients (age ≥18 years)
presenting to the ED were electronically screened for in-
clusion. Exclusion criteria were: (1) multi-system trauma;
(2) discharge from the ED; (3) hemoglobin <7 g/dl; (4)
transfer to another hospital from the ED; and (5) death
in the ED. The study population was restricted to those
patients with a hemoglobin level ≥7 g/dl, as guideline
recommendations suggest considering a transfusion
below this threshold. Multi-system trauma patients were
also excluded, as little controversy exists regarding
transfusion in the setting of major hemorrhage.
Matching
All adult patients admitted to the ED were identified as
having received blood product transfusion (cases) in the
ED by electronic registry query and verified by review of
the medical record. Blood products were defined as
packed red blood cells (PRBCs), fresh frozen plasma
(FFP), or platelets. Using the same exclusion criteria,
along with an electronic screen to identify patients with
similar presenting diagnoses, non-transfused patients
(controls) that were admitted to the ED over the same
time period were identified. The a priori matching
strategy was designed based on the assumption that the
decision to transfuse blood products in the ED would be
based upon the presence of a bleeding condition, labora-
tory values (i.e., hemoglobin), and age. Therefore,
patients were matched one-to-one for key indicators for
transfusion: ED diagnosis, hemoglobin value, age, and
gender. The matching criteria were: diagnosis (same),
hemoglobin (±1 g/dl), age (±5 years), and gender (same)
in this order. Non-matched cases were discarded.
Measurements and key outcome measures
Baseline demographics, comorbid conditions, vital signs
at ED presentation, laboratory values, illness severity, ED
length of stay, and ED diagnosis were collected from the
electronic medical record. Definitions of comorbid
conditions are provided in Additional file 1. Sepsis was
defined as previously described [13]. Process of care var-
iables in the ED included intravenous fluid, endotracheal
intubation, central venous and arterial catheter place-
ment, antibiotics, and vasopressor infusion. To ensure
uniform data collection and accuracy, all variables were
defined prior to data extraction and placed in a stan-
dardized format during the data collection process.
Regular meetings and monitoring of data collection were
performed, with verification of data accuracy and cross-
checking of all data with electronic medical records.
After admission, blood products transfused during the
first 24 h were collected. Fluid balance was recorded
daily over the first 3 days. Patients were followed until
hospital discharge or death.
The primary outcome was a composite pulmonary
outcome that included: acute respiratory failure, new need
for ICU admission, and the presence of ARDS. This out-
come was chosen a priori as it accounted for potential
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complications and clinical deterioration associated with
transfusion occurring both in patients not initially requir-
ing ICU admission, and those critically ill during ED pres-
entation. The primary outcome was restricted to the first
3 days to better examine a temporal link between ED
transfusion and complications, including lung injury at
72 h (i.e., “delayed TRALI syndrome”) [14]. Acute re-
spiratory failure was defined as the need for invasive or
non-invasive ventilation in patients not initially requir-
ing positive pressure support in the ED. New need for
ICU admission was defined as the need for ICU admis-
sion in patients initially admitted from the ED to the
general ward. ARDS was defined according to the Berlin
definition and adjudicated, by co-investigators blinded
to transfusion status, as previously described [15–17].
Secondary outcomes included ventilator-, hospital-,
and ICU-free days, the need for renal replacement ther-
apy (RRT), as well as hospital mortality.
Data analysis
Descriptive statistics, including mean [standard deviation
(SD)], median [interquartile range (IQR)], and frequency
distributions were used to assess the characteristics of
the patient cohort. Continuous and categorical variables
were compared using an unpaired t test, Mann-Whitney U
test, Chi-square test, or Fisher’s exact test, as appropriate.
To assess predictors of the primary outcome, covariates
associated with the outcome at P < 0.10 were candidates
for inclusion in a bidirectional stepwise, multivariable lo-
gistic regression analysis. The stepwise regression method
selected variables for inclusion or exclusion from the
model in a sequential fashion based on the significance
level of 0.10 for entry and 0.10 for removal. Collinearity
was assessed, and the model used variables that contrib-
uted information that was statistically independent of the
other variables in the model. The Hosmer-Lemeshow test,
along with the examination of residuals, was used to assess
model goodness of fit. Adjusted odds ratios (aORs) and
corresponding 95% confidence intervals (CI) are reported
for variables in the multivariable model, adjusted for all
variables in the model.
The expected event rate for the primary outcome in
the cases was 20% [3, 8, 16, 18–20]. We estimated that
with a sample of 204 patients per group, the study would
have 80% power to detect an absolute reduction of 5%,
with a two-sided type I error rate of 5%.
Results
Study population
A total of 2257 transfused patients were assessed for
inclusion. A total of 204 matched pairs were included in
the final study population (Fig. 1).
Baseline characteristics of the study population are
shown in Table 1. The matching strategy yielded a study
cohort with similarities in age, gender, ED diagnosis, and
hemoglobin values. With respect to other baseline char-
acteristics, in the transfusion group, there was a higher
incidence of cirrhosis, along with higher values for INR
and bilirubin. With respect to process of care variables,
the transfusion group received approximately 600 mL
Fig. 1 Flow diagram
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more of intravenous fluid (P < 0.001), had a higher inci-
dence of central venous catheter use in the ED (20.1 vs.
7.4%, P < 0.001), and were admitted directly to the ICU
from the ED more frequently (41.2 vs. 24.5%, P < 0.001).
Transfusion characteristics
A total of 124 (60.8%) patients were transfused PRBCs
in the ED (Table 2). A mean of 1.9 (±0.8) units per
patient was transfused. The most common indications
for transfusion were hemorrhage (29.0%), infection
(18.5%), anemia (16.9%), and cardiac (9.7%). The mean
pre-transfusion hemoglobin level was 8.5 g/dl. There
were 73 patients with an initial hemoglobin value ≥10 g/dl;
Table 1 Baseline characteristics
Controls: no
transfusion in ED
group (n = 204)
Cases:
transfusion
group (n = 204)
P value
Matching criteria
Age (years) 62.4 (14.9) 62.0 (15.3) 0.78
Male, n (%) 103 (50.5) 96 (47.1) 0.49
ED diagnosis, n (%)
Gastrointestinal
hemorrhage
49 (24.0) 45 (22.1) 0.64
Infection 44 (21.6) 39 (19.1) 0.54
Cardiaca 20 (9.8) 17 (8.3) 0.61
Neurological injury 20 (9.8) 25 (12.3) 0.43
Anemia 20 (9.8) 22 (10.8) 0.74
Metabolicb 11 (5.4) 13 (6.4) 0.67
Emergency surgery 10 (4.9) 13 (6.4) 0.52
Liver disease 8 (3.9) 7 (3.4) 0.79
Thrombocytopenia 7 (3.4) 8 (3.9) 0.79
Hypotension 6 (2.9) 9 (4.4) 0.43
Hemorrhage (other) 5 (2.5) 4 (2.0) 0.74
Excessive
anticoagulation
1 (0.5) 1 (0.5) 1.0
Other 3 (1.5) 1 (0.5) 0.31
Hemoglobin 9.6 (2.1) 9.5 (2.3) 0.87
Other baseline characteristics
Race, n (%)
Caucasian 105 (51.5) 114 (55.9) 0.37
African-American 96 (47.1) 83 (40.7) 0.19
Other 3 (1.5) 7 (3.4) 0.20
Comorbidities, n (%)
Diabetes 83 (40.7) 69 (33.8) 0.15
Cirrhosis 27 (13.2) 50 (24.5) 0.004
CHF 42 (20.6) 29 (14.2) 0.09
Dialysis 21 (10.3) 8 (3.9) 0.01
Malignancy 66 (32.4) 69 (33.8) 0.75
COPD 30 (14.7) 28 (13.7) 0.78
Immunosuppression 36 (17.6) 47 (23.0) 0.18
Alcohol abuse 29 (14.2) 24 (11.8) 0.46
Emergency surgery 5 (2.5) 3 (1.5) 0.48
Height (in) 66.5 (4.2) 66.7 (4.5) 0.62
Weight (kg) 81.9 (27.9) 78.5 (26.2) 0.21
PBW (kg) 62.6 (11.1) 63.3 (12.0) 0.57
BMI 28.7 (9.3) 27.4 (9.2) 0.14
Temperature (celsius) 36.8 (0.7) 36.8 (0.8) 0.43
RR 18.6 (3.1) 18.4 (2.8) 0.68
SBP 129.1 (33.6) 122.7 (34.1) 0.06
DBP 72.5 (17.6) 71.4 (17.6) 0.53
Table 1 Baseline characteristics (Continued)
Lactate (n = 161) 1.5 (1.0–2.7) 2.1 (1.2–3.6) 0.04
Creatinine 1.3 (0.8–2.4) 1.1 (0.8–1.6 0.01
WBC 10.2 (8.4) 10.1 (6.6) 0.88
Platelet 213.6 (146.7) 192.7 (146.5) 0.15
INR 1.6 (1.1) 2.1 (1.7) 0.001
Total bilirubin 0.5 (0.3–0.9) 0.7 (0.4–1.4) 0.001
Albumin 3.3 (0.7) 3.2 (0.8) 0.14
SOFAc 4.0 (2.9) 3.6 (2.7) 0.25
Source of admission, n (%)
Home 151 (74.0) 140 (68.6) 0.23
Transferring facility 35 (17.2) 41 (20.1) 0.45
Nursing home 18 (8.8) 23 (11.3) 0.41
Sepsis, n (%) 64 (31.4) 73 (35.8) 0.35
ED LOS (hours) 7.1 (5.2–9.7) 8.3 (6.0–11.9) 0.01
Process of care variables
Intravenous fluids in ED
(liters)
1.2 (1.5) 1.8 (1.6) <0.001
Intubated in ED, n (%) 15 (7.4) 24 (11.8) 0.13
Tidal volume, mL/kg
PBW
7.3 (6.4–9.0) 8.5 (7.7–10.2) 0.11
Central venous catheter,
n (%)
15 (7.4) 41 (20.1) <0.001
Arterial catheter, n (%) 8 (3.9) 8 (3.9) 1.0
Antibiotics, n (%) 78 (38.2) 85 (41.7) 0.48
Vasopressor infusion,
n (%)
16 (7.8) 23 (11.3) 0.24
Admitted to ICU, n (%) 50 (24.5) 84 (41.2) <0.001
ED emergency department, CHF congestive heart failure, COPD chronic
obstructive pulmonary disease, PBW predicted body weight, BMI body mass
index, RR respiratory rate, SBP systolic blood pressure, DBP diastolic blood
pressure, WBC white blood cell, INR international normalized ratio, SOFA
sequential organ failure assessment score, LOS length of stay, ICU intensive
care unit
Continuous variables are reported as mean (standard deviation) and median
(interquartile range)
aIncludes the diagnoses of sudden cardiac arrest, heart failure, syncope, acute
coronary syndrome, and arrhythmia
bIncludes the diagnoses of rhabdomyolysis, acute kidney injury, hypoglycemia,
diabetic ketoacidosis, and electrolyte abnormalities
cModified score, which excludes Glasgow Coma Scale
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19 (26.0%) received a PRBC transfusion. Sixty-four (31.4%)
patients were transfused FFP in the ED. A mean of 2.2
(±0.9) units per patient was transfused. The most common
indications for transfusion were hemorrhage (23.4%),
neurologic injury (20.3%), infection (12.5%), and emergency
surgery (10.9%). The mean international normalized ratio
(INR) prior to transfusion was 3.3. A total of 54 (26.5%)
patients were transfused platelets in the ED. A mean of 1.4
(±0.5) units per patient was transfused. The most common
indications were thrombocytopenia (27.8%), neurologic
injury (24.1%), infection (18.5%), and hemorrhage (14.8%).
Of the patients transfused for thrombocytopenia ten
(66.7%) had a platelet level <10,000 (guideline recom-
mended threshold for transfusion to prevent spontaneous
hemorrhage). The mean platelet count for the neurologic
injury patients was 197,000 prior to transfusion.
During the first 24 h after ED admission, cases were
transfused PRBC less frequently compared to controls
(23.5 vs. 43.1%, P < 0.001); there was a higher incidence of
FFP transfusion among the cases (11.8 vs. 5.4% P = 0.02).
There was no difference in the incidence of platelet
transfusion between the cases and controls (10.3 vs. 6.4%,
P = 0.15) after admission.
Fluid balance after admission
There was a significant difference in net fluid balance
during the first 3 days of admission, control group 1.1 l
(±3.5) vs. 2.1 l (±4.5) in the cases, P = 0.01, Fig. 2.
Outcomes
The primary outcome occurred in 26 control patients
(12.7%), as compared with 28 cases (13.7%). In multivari-
able logistic regression analysis, adjusting for body mass
index, sepsis, shock (i.e., vasopressor use), ED mechanical
ventilation, and fluid balance, ED transfusion was not
associated with an increased odds of primary outcome
[adjusted OR 0.91 (0.48–1.72), P = 0.77; Table 3].
Ventilator-, ICU-, and hospital-free days were approxi-
mately 1 day higher in the control group; this did not reach
statistical significance. The incidence of RRT was 8.8% in
the controls and 3.4% in the cases, P = 0.02. There was no
difference in the mortality rate between the two groups.
Table 2 Transfusion variables for the 204 patients transfused in the emergency department
Blood product
Packed red blood cells Fresh frozen plasma Platelets
Number (%) 124 (60.8) 64 (31.4) 54 (26.5)
Mean (SD) 1.9 (0.8) 2.2 (0.9) 1.4 (0.5)





Neurologic injury, 13 (20.3)
Infection, 8 (12.5)
Emergency surgery, 7 (10.9)
Thrombocytopenia, 15 (27.8)
Neurologic injury, 13 (24.1)
Infection, 10 (18.5)
Hemorrhage, 8 (14.8)
Hemoglobin (g/dl) 8.5 (1.7) 10.4 (2.5) 10.7 (2.3)
INR 1.8 (1.4) 3.3 (2.3) 1.5 (1.0)
Platelet 223 (155) 184 (117) 82 (94)
Cardiac: includes the diagnoses of sudden cardiac arrest, heart failure, syncope, acute coronary syndrome, and arrhythmia
Fig. 2 Fluid balance (mL) during the first 3 days of admission. There was a significant difference in net fluid balance during the first 3 days of
admission, controls 1.1 l (3.5) vs. 2.1 l (4.5) in the cases, P = 0.01
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There were 70 patients transfused in both the ED and
during the first 24 h after admission. The primary
outcome occurred in 16 (22.9%) of these patients, as
compared with 38 (11.2%) patients that did not receive
blood product at both time points [OR 2.34 (1.22–4.49),
P = 0.009]. There was no mortality difference, 14.3 vs.
8.9%, P = 0.17.
Discussion
On the strength of a number of randomized trials and
observational studies in the critical care and peri-
operative setting, several guidelines regarding blood
product transfusion have been published [5, 21, 22]. The
most evidence-based, and physiologically sound, indica-
tions for blood product transfusion are for the treatment
of life-threatening hemorrhage or coagulopathy, preven-
tion of hemorrhage in the peri-operative/procedural set-
ting, and anemia with evidence of tissue hypoperfusion.
Transfusion in the ED could be beneficial if it serves to:
(1) improve early hemostasis, resulting in less overall
transfusion requirements; or (2) reverse early tissue hy-
poperfusion, resulting in less subsequent organ failure. It
could also be harmful if it promotes transfusion-related
complications. However, there is a paucity of data from
the ED regarding both transfusion practices and the
potential impact on outcome. Results of this case-
control study provide some initial data in this domain.
The most common transfusion indication for PRBCs
was hemorrhage (primarily gastrointestinal) and infection.
The mean hemoglobin level of 8.5 mg/dl is fairly consist-
ent with multicenter observational studies in general ICU
patients, however a 26% transfusion rate for patients with
a hemoglobin ≥10 g/dl suggests discordance between ED
transfusion practices and guideline recommendations [1].
Another significant finding was the frequency of platelet
transfusion in the setting of neurologic injury (24.1% of
platelet transfusions). A mean platelet count of 197,000 in
these patients suggests transfusion was driven by a history
of anti-platelet therapy, which is a common practice in
our center. The majority of evidence does not support this
practice [23, 24].
With respect to clinical outcomes, there was no
significant difference between the two groups, contrary
to both our a priori hypothesis and the majority of previ-
ous data showing an association of harm with transfu-
sion in the critically ill patient. There are several
possible explanations. Transfusion therapy is likely safer,
owing to improved blood preparation and leukocyte
depletion. Our results are congruent with a more recent
observational study that not only failed to show harm in
transfusion, but showed greater survival in a propensity-
matched analysis [25]. An updated randomized trial
would be the only means to test this hypothesis
adequately [3]. Another important factor could be the
issue of timing. ED transfusion may serve to reverse
early tissue hypoperfusion and mitigate organ failure.
This is supported by a lower incidence of RRT in the
transfusion group. ED transfusion may also reduce
complications by limiting overall transfusion require-
ments if it promotes hemostasis and tissue perfusion
earlier. In the current study, during the first 24 h after
ED admission, cases were transfused PRBC less fre-
quently compared to controls, which may have served
to limit the dose-response effect that was observed in
patients transfused in both the ED and after admission.
This study has several important limitations. Our ana-
lysis did not include all patients transfused in the ED,
and was restricted to the number needed based upon
the sample size calculation. The results, especially
descriptive data regarding transfusion practices, could
Table 3 Primary and secondary outcomes according to study group
Outcome Controls: no transfusion
in ED group (n = 204)
Cases: transfusion
group (n = 204)
Odds ratio or between-group
difference (95% CI)
P value*
Primary composite outcome, n (%) 26 (12.7) 28 (13.7) 0.91 (0.48–1.72) 0.77
• Respiratory failure 17 (8.3) 19 (9.3) 1.13 (0.57–2.24) 0.73
• ICU admission 8 (3.9) 7 (3.4) 0.87 (0.31–2.45) 0.79
• ARDS 9 (4.4) 14 (6.9) 1.60 (0.68–3.78) 0.28
Secondary outcomes (days)
Ventilator-free 24.7 (9.4) 23.7 (10.3) 1.0 (−0.9–2.9) 0.30
ICU-free 24.7 (8.3) 23.7 (9.0) 0.9 (−0.8–2.6) 0.30
Hospital-free 20.0 (8.5) 18.6 (9.1) 1.4 (−0.3–3.1) 0.11
RRT, n (%) 18 (8.8) 7 (3.4) 0.37 (0.15–0.90) 0.02
Mortality, n (%) 18 (8.8) 22 (10.8) 1.25 (0.65–2.41) 0.51
The primary outcome was a composite outcome that combined the event rate for respiratory failure, ICU admission, and acute respiratory distress syndrome
*P value for the primary outcome measure was a Wald test estimated using a logistic regression model adjusting for body mass index, sepsis, shock
(i.e., vasopressor use), ED mechanical ventilation, and fluid balance
*P values for the secondary outcomes are from the Chi-square test (categorical data) and the independent sample t test (continuous data)
CI confidence interval, ICU intensive care unit, ARDS acute respiratory distress syndrome, RRT renal replacement therapy
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have been different had the entire transfused sample
been included. This highlights the need for further ob-
servational and epidemiological data in this domain. The
study cohort was not restricted to ICU patients, and our
event rate for complications could have been higher had
we limited the analysis to ICU admissions. However, our
current approach better describes the majority of ED
transfusions and is therefore more generalizable. Patients
with a hemoglobin <7 g/dl were also excluded. As there
is less controversy regarding the risk: benefit of transfu-
sion in this cohort, we wanted to restrict the analysis to
patients in whom a transfusion could have potentially
been avoided. While we excluded patients with trau-
matic hemorrhage, those with hemorrhage (potentially
major) from a gastrointestinal source were included.
This provides valuable descriptive data, but could have
further confounded results by including a patient group
with a clear indication for transfusion. The cases and
controls were well-matched with respect to the a priori
matching strategy. However, the cases were potentially a
sicker cohort, as demonstrated by a higher ICU admit-
tance rate and greater fluid administration. However,
this should have biased our results toward the primary
hypothesis, which was not the case.
Conclusions
In this case-control study, a significant percentage of ED
blood product transfusions were discordant with current
guideline recommendations. However, there was no asso-
ciation with ED transfusion and worse clinical outcome.
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